Lonza, Agennix JV for talactoferrin production

Rajesh Malik, Chief Medical Officer and Management Board member, Agennix.

BASEL, SWITZERLAND/MUNICH, GERMANY: Lonza and Agennix signed an agreement for the production of Agennix’s first-in-class oral dendritic cell mediated immunotherapy (DCMI), talactoferrin, currently in Phase III testing for the treatment of non-small cell lung cancer (NSCLC). Lonza will produce commercial material at its microbial manufacturing facility in Kourim, Czech Republic. This agreement initiates the process needed to ultimately seek approval for Lonza as a second manufacturer of talactoferrin after the initial commercial launch. 

“Lonza has extensive experience manufacturing biologics on a commercial scale. In anticipation of positive Phase III data and a potential product approval, it is important that we have more than one manufacturer in place to ensure we can meet anticipated commercial demand and that we have security of supply,” said Rajesh Malik, Chief Medical Officer and Management Board member, Agennix.

© WOC News